Kiadis and Biofrontera Team Up to Develop Drugs for Pain

Biofrontera has identified the new disease targets that will form the starting point of the collaboration, using its proprietary method for DNA analysis, called Digital Expression Pattern Display (DEPD). The company will be responsible for the in vitro and in vivo profiling of the compounds that have been identified by Kiadis as well as the full profiling of the leads that have been optimized. Kiadis will apply its proprietary High Resolution Screening (HRS) technology to complex mixtures of molecules derived from product libraries to identify molecules that possess specific bioactivity against the selected targets generated by Biofrontera.

"This collaboration clearly strengthens Biofrontera's technology portfolio to speed up the identification of new therapeutics for our innovative drug targets for neuropathic pain,” said Prof. Hermann Lubbert, president and CEO of Biofrontera. The company has a first project in phase II clinical trials.





Related Links:
Kiakis
Biofrontera